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ACUTE STROKE CARE: HOW CAN 
MODERN STROKE CARE BE MADE 
AVAILABLE TO MORE PATIENTS?
Much progress has been made in acute 
stroke management during the last 20 years. 
Today we can offer organized stroke unit 
care in many regions in Europe and some 
in the United States and Canada; we have 
an approved acute medical treatment for 
ischemic stroke, i.v. rtPA. Clot retrieval 
devices are approved and available and we 
have evidence-based treatment strategies 
for critically ill stroke patients. A number 
of promising new approaches, still await 
formal evidence, although they are already 
used quite frequently.
However, this progress is not available 
everywhere. There are large disparities 
between what is known and what can be 
offered in many countries and regions 
throughout the world. The standard of 
care in some regions is far from routine in 
others, or may be available only at selected 
places for very few privileged people. 
Unfortunately, there is no uniform way in 
which the application and expansion of 
what we know in acute stroke management 
can be promoted throughout the world. 
Rather, individual routes must be defi ned 
with respect to availability of resources, 
standards of training and teaching, and 
priorities in health economics.
The establishment of Stroke Units and 
Stroke Centers has been the most valuable 
contribution to the fi eld of acute stroke 
management. It is not only the single most 
effective intervention for the vast majority 
of stroke patients, but it is also a major factor 
towards increasing the number of patients 
receiving thrombolytic therapy. Together 
with pre-hospital system organisation 
and access to rehabilitation and secondary 
prevention, these are the most important 
columns on which the expansion of stroke 
treatment is built.
Once “Stroke” has reached political 
awareness, implementation of care sys-
tems proceeds more smoothly. The politi-
cal will to improve stroke care will allow 
new activities in the fi eld of stroke to be 
launched. Nation- or statewide docu-
mentation, standards, and quality control 
instruments can be implemented, and more 
fi nancial resources will be made available 
for the development of stroke management 
and prevention. Stroke care is expensive, 
and stroke care has to be paid out of the 
shrinking budgets of general health care. 
Increasing the resources for one area means 
cutting resources in others, not an action 
that will be warmly welcomed by colleagues 
in other fi elds.
Although capitalizing on existing ther-
apies is well justifi ed, fl exibility has to be 
built into the system to facilitate the suc-
cessful investigation and application of new 
diagnostic and therapeutic approaches as 
they are developed. By doing so, the stroke 
care system will remain fl exible and will 
be amenable to incorporate advances that 
will continue to improve the care of the 
stroke patient.
We propose a stepwise approach to 
improvement of stroke care.
STEP 1: INCREASE STROKE AWARENESS
Main barriers for stroke treatment are 
the lack of the recognition of stroke signs 
and the lack of a sense of urgency to seek 
help. Campaigns of stroke awareness can 
decrease the time from symptoms onset to 
the hospital and increase the number of 
treated patients. Multi modal media cam-
paigns that improve public information 
about acute stroke signs and the urgency 
to call pre-hospital emergency medical 
systems must be developed and imple-
mented in the different regions. Public 
education campaigns should encourage 
not only affected individuals, but also fam-
ily and bystanders to call the pre-hospital 
emergency medical system if they observe 
an individual having signs of a possible 
stroke.
STEP 2: IMPROVE EMERGENCY STROKE CARE
Activating the prehospital emergency 
medical system in acute stroke care is 
associated with a shorter delay to arrival 
at hospital. The training of ambulance team 
and dispatchers in prehospital recognition 
of stroke as an emergency and the recogni-
tion of stroke signs increases the number 
of patients arriving earlier at hospital. 
Training of pre-hospital emergency medi-
cal systems team to recognize stroke and to 
bring acute stroke patients directly to desig-
nated stroke centers is key to improvement 
of overall stroke care. Regional networks 
of stroke care between pre-hospital emer-
gency medical systems and stroke centers 
must be established.The same telephone 
number in whole country to activate the 
pre-hospital emergency medical system is 
needed (the European 112 and USA 911-
campaigns).
STEP 3: ESTABLISHMENT OF STROKE CENTERS 
AND STROKE UNITS TO ASSIST ACUTE STROKE 
PATIENTS AS A PRIORITY
Efforts should be made to establish Stroke 
Center hospitals with organized Stroke 
Units in locations nearby and accessible 
to all stroke patients to reduce the burden 
of stroke in the world. These specialized 
centers should be organized according to 
local and regional needs and classifi ed in 
different levels of complexity according 
to the resources and treatments available 
in each. Stroke Centers should implement 
evidence based protocols, including throm-
bolytic therapy. Hospitals in each city or 
region should be identifi ed as stroke cent-
ers with organized Emergency Department 
and Stroke Unit care in accordance with 
Local Health Authorities. Stroke Units and 
Stroke Centers must be classifi ed and cer-
tifi ed according to standard defi nitions. 
Quality standards and minimum quanti-
ties of interventions and procedures must 
be established. Specialized staff must be 
trained with standardized protocols includ-
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evaluation of each patient by the  funding 
agency. In fact, many centers now evalu-
ate patients thoroughly as part of the 
normal work-up.
An alternative is to have trials 
that study only subgroups, for exam-
ple trials that consider only patients 
with atrial fibrillation or stenosis of 
the basilar artery, or ischemia due to 
penetrating artery disease (“lacunar 
stroke”).
2) How to make guidelines more fl exible 
and more related to the context of the 
individual patient being treated?
Some guidelines slavishly repeat the 
inclusions and exclusions of trials and give 
absolute rules applicable to all patients. 
Payers use these absolutes to deny pay-
ment, and lawyers use these guidelines 
in medical malpractice suits against phy-
sicians who deviate from the absolutes. 
Instead, guidelines should begin by stating 
the theory behind selection of treatment 
and variables to be considered. Guidelines 
should disclose the populations studied in 
trials that were used to generate the reco-
mendations, and should acknowledge 
which if any subgroups were specifi cally 
studied. What if language is helpful in giv-
ing context to decisions; for example in 
thrombolytic guidelines, What if a patient 
is seen after a defi ned time (such as 4.5 h) 
and has an intracranial occlusive lesion 
and a signifi cant diffusion/perfusion mis-
match. Physician judgement and patient 
and family input will always be applicable 
for individual patient decisions and lan-
guage acknowledging that reality should 
be included in guidelines.
We challenge authors to submit articles 
about the conduct of trials, defi nition and 
management of stroke subgroups and about 
stroke guidelines.
LEARNING MORE ABOUT RECOVERY 
FROM STROKE AND THE 
EFFECTIVENESS OF VARIOUS 
REHABILITATION STRATEGIES
Stroke will never be completely conquered 
by hyperacute treatment after symptoms 
of neurological dysfunction develop. 
A great many stroke patients will never 
arrive at major stroke centers in time for 
hyperacute treatment. Even then many 
of those treated will have residual neuro-
logical deficits. Little of scientific valid-
that aspirin has some effectiveness against 
brain ischemia, there may be no evidence 
that it is effective or ineffective for a given 
vascular disorder unless it has been specifi -
cally tested for that disorder. Even when 
it has been tested for that disorder, coex-
isting factors in a particular patient often 
complicate the decision about whether or 
not to use a particular agent in a particular 
patient at a particular time. Therapeutic 
decisions are often complex and require 
experienced physicians. Treatment deci-
sions for individual patients cannot be 
made by protocols, rules, or computer 
searches. Evidence from trials, past expe-
rience, and intimate detailed knowledge of 
the patient, the diseases, and the wishes 
and desires of all concerned are required 
to make diffi cult therapeutic decisions. 
Non-physicians (commonly insurers and 
payers) should not be allowed to control 
this decision making process by mandating 
guidelines that are infl uenced mostly by 
cost considerations.
The challenge is two-fold.
1) How to make trials and trial results 
more useful for treatment of individual 
patients?
One key strategy to make results more 
useful is defi ning meaningful subgroups 
within a trial. Using cerebrovascular dis-
ease as an example, this would require 
mandating that all patients have thor-
ough analyses of potential cardio- cer-
vico-cranial vascular, and hematological 
causes of brain ischemia, and reporting 
of the nature, location and severity of 
steno-occlusive lesions and brain inf-
arcts and hemorrhages. Subgroups can 
be managed either by prospective strati-
fi cation, that is, by randomizing patients 
using predetermined criteria (e.g., sex, 
race, age, vascular lesions, stroke sub-
types) to ensure that subgroups will be 
relatively equally represented in the dif-
ferent treatment groups, or by analyz-
ing the treatment results by subgroup 
determinants that have been prospec-
tively defi ned but the subgroups must 
also be very large to satisfy statisticians. 
An issue that has been problematic is 
paying for such large trials. Mandating 
a thorough evaluation means that the 
funding agency mmust pay fort hat 
evaluation-greatly increasing the cost of 
ing the implementation of thrombolytic 
therapy for acute ischemic stroke. Quality 
control instruments must be implemented 
and made compulsory.
We challenge authors to submit reports 
about translation of knowledge about stroke 
and its treatments into practical delivery of 
stroke care to patients.
IMPROVING THE APPLICABILITY OF 
EVIDENCE-BASES TO THE CARE OF 
INDIVIDUAL PATIENTS AND INCLUDING 
FLEXIBILITY AND CONTEXT INTO 
GUIDELINES
Everyone desires their approach to diag-
nosis and treatment to be evidence-based. 
Although some defi ne evidence-based as 
determined only by the results of prospec-
tive randomized double-blind therapeu-
tic trials, most physicians use different 
types of evidence, not all equal, to decide 
on treatment for individual patients. 
Randomized trials have defi nite limita-
tions. The major theoretical limitation 
of trials is the issue of numbers vs spe-
cifi city. For trials to yield statistically valid 
and important results, they must include a 
very large quantity of patients – numbers. 
For the results to be useful to practicing 
physicians, the data must be specifi cally 
applicable to individual patients who have 
the condition studied. To include enough 
patients, the condition studied must be 
common and usually multiple physicians 
at many medical centers must be used. A 
single doctor or center would have too few 
patients or would take an unacceptably 
long time to enroll and study the number 
of required patients. To achieve numbers, 
a “lumping” strategy must predominate 
over “splitting.”
Information from trials must be weighted 
according to the context of specifi c treat-
ment decisions. Conducting trials is differ-
ent from caring for individual patients. In 
trials, the same treatments are given to all 
eligible patients depending only on rand-
omization. Departure from the specifi ed 
treatment makes the results diffi cult to 
interpret. In the clinic, doctors treat indi-
vidual patients.
Courts continuously wrestle with the 
issue of the applicability of general laws 
and precedence from prior individual cases 
to the case being considered. For example, 
although there may be general evidence 
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We challenge authors to submit material 
about stroke recovery and its treatment.
CLINICAL AND EPIDEMIOLOGICAL 
FEATURES OF STROKE AND 
CEREBROVASCULAR DISEASE AND 
THEIR DIAGNOSIS AND MANAGEMENT
Frontiers in Stroke is interested in receiv-
ing new information on all aspects of 
 cerebrovascular disease.
ity is now known about recovery from 
neurological deficits including stroke. 
The development of improved diagnos-
tic technology including functional MRI 
and newer treatment modalities includ-
ing magnetic and electrical stimulation 
provide an opportunity to study more 
scientifically how individuals recover and 
what strategies facilitate or impede natu-
ral recovery.
